Is This A Miracle Drug For ‘Sticky Cholesterol’? Analysts Applaud Safety, Efficacy Of Silence Therapeutics’ Heart Disease Candidate

Silence Therapeutics plc (NASDAQ: SLN) announced topline results from the multiple-dose component of the APOLLO phase 1 study of zerlasiran (formerly SLN360) in 36 adults with baseline lipoprotein(a) …


Posted

in

by

Tags: